Boston Family Office LLC Acquires 4,258 Shares of Moderna, Inc. (NASDAQ:MRNA)

Boston Family Office LLC increased its holdings in shares of Moderna, Inc. (NASDAQ:MRNA) by 83.8% in the third quarter, according to its most recent filing with the SEC. The fund owned 9,342 shares of the company’s stock after acquiring an additional 4,258 shares during the period. Boston Family Office LLC’s holdings in Moderna were worth $624,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also recently modified their holdings of the business. Charles Schwab Investment Management Inc. raised its position in Moderna by 4.1% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 2,132,777 shares of the company’s stock valued at $142,533,000 after purchasing an additional 83,082 shares in the last quarter. Sumitomo Mitsui Trust Group Inc. raised its position in Moderna by 11.6% during the 3rd quarter. Sumitomo Mitsui Trust Group Inc. now owns 1,614,313 shares of the company’s stock valued at $107,885,000 after purchasing an additional 167,596 shares in the last quarter. Dimensional Fund Advisors LP raised its position in Moderna by 2.1% during the 2nd quarter. Dimensional Fund Advisors LP now owns 1,427,300 shares of the company’s stock valued at $169,542,000 after purchasing an additional 29,566 shares in the last quarter. ARK Investment Management LLC increased its holdings in shares of Moderna by 10.4% in the 3rd quarter. ARK Investment Management LLC now owns 1,163,946 shares of the company’s stock valued at $77,787,000 after acquiring an additional 109,852 shares during the period. Finally, Swiss National Bank increased its holdings in shares of Moderna by 0.3% in the 3rd quarter. Swiss National Bank now owns 966,800 shares of the company’s stock valued at $64,611,000 after acquiring an additional 3,200 shares during the period. 75.33% of the stock is owned by institutional investors.

Insider Buying and Selling

In related news, CFO James M. Mock sold 715 shares of the company’s stock in a transaction dated Monday, October 7th. The stock was sold at an average price of $60.12, for a total value of $42,985.80. Following the completion of the transaction, the chief financial officer now owns 9,505 shares of the company’s stock, valued at approximately $571,440.60. This represents a 7.00 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. In the last 90 days, insiders sold 2,930 shares of company stock valued at $217,170. 15.20% of the stock is owned by company insiders.

Moderna Stock Performance

Shares of MRNA stock opened at $43.66 on Tuesday. The stock has a market cap of $16.80 billion, a PE ratio of -7.50 and a beta of 1.69. The business has a 50-day simple moving average of $54.96 and a 200-day simple moving average of $93.71. The company has a quick ratio of 4.20, a current ratio of 4.39 and a debt-to-equity ratio of 0.05. Moderna, Inc. has a 52-week low of $35.80 and a 52-week high of $170.47.

Moderna (NASDAQ:MRNA) last issued its quarterly earnings data on Thursday, November 7th. The company reported $0.03 earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.89) by $1.92. The business had revenue of $1.90 billion during the quarter, compared to analysts’ expectations of $1.25 billion. Moderna had a negative return on equity of 17.68% and a negative net margin of 43.77%. The company’s revenue for the quarter was up 3.8% on a year-over-year basis. During the same quarter in the previous year, the firm posted ($1.39) EPS. On average, equities analysts expect that Moderna, Inc. will post -9.44 EPS for the current year.

Wall Street Analyst Weigh In

A number of research analysts have recently issued reports on MRNA shares. Berenberg Bank started coverage on Moderna in a report on Tuesday, November 19th. They issued a “hold” rating and a $42.00 price target on the stock. Jefferies Financial Group dropped their target price on Moderna from $65.00 to $55.00 and set a “hold” rating on the stock in a research note on Tuesday, October 15th. Wolfe Research began coverage on Moderna in a research note on Friday, November 15th. They set an “underperform” rating and a $40.00 target price on the stock. Oppenheimer downgraded Moderna from an “outperform” rating to a “market perform” rating in a research note on Friday, September 13th. Finally, Deutsche Bank Aktiengesellschaft upgraded Moderna from a “sell” rating to a “hold” rating and dropped their target price for the stock from $85.00 to $80.00 in a research note on Wednesday, August 7th. Three investment analysts have rated the stock with a sell rating, thirteen have assigned a hold rating, five have assigned a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat.com, the stock has an average rating of “Hold” and an average price target of $84.00.

About Moderna

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.